
    
      -  Safety/ Tolerability evaluation Adverse events, Physical examinations, Vital signs, ECG
           (including continuous ECG monitoring), Laboratory tests (including hematology,
           chemistry, coagulation, PBS, NAD(P)+/NAD(P)H ratio, urinalysis), CIC

        -  Pharmacokinetic Evaluation(single)

             -  Serial blood samples and urine collections for pharmacokinetic evaluations will be
                conducted between 0 (pre-dose) and 96 hours after a single oral dose.

             -  Blood sampling time pre-dose, 0.5, 1h, 2h, 3h, 4h, 6h, 8h, 10h, 12h, 16h, 24h, 36h,
                48h, 72h post-dose

             -  Urine collection time 0h - 6h, 6h - 12h, 12h - 24h, 24h - 48h, 48h - 72h

             -  Evaluation parameters AUClast, AUCinf, Cmax, Tmax, t1/2, Vd/F, CL/F, Ae, fe, CLR

        -  Pharmacokinetic Evaluation(multiple)

             -  Serial blood samples and urine collections for pharmacokinetic evaluations will be
                conducted after a single oral dose and Steady state.

             -  Blood sampling time Day 1 pre-dose, 0.5h, 1h, 2h, 3h, 4h, 6h, 8h, 10h, 12h, 16h,
                24h, Day3-6 Pre-dose, Day7 Pre-dose, 0.5h, 1h, 2h, 3h, 4h, 6h, 8h, 10h, 12h, 16h,
                24h, 36h, 48h, 72h, 96h post-dose

             -  Urine collection time Day 1 Pre-dose, 0h - 6h, 6h - 12h, 12h - 24h, Day 7 Pre-dose,
                0h - 6h, 6h - 12h, 12h - 24h

             -  Evaluation parameters Cmax,ss, Cmin,ss, Cav,ss, AUCÏ„, Tmax,ss, t1/2, PTF(peak to
                trough fluctuation ratio), fe, CLss/F, CLR
    
  